Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=other_investigators", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=other_investigators" }, "data": [ { "type": "Grant", "id": "7040", "attributes": { "award_id": "3R01DA043409-04S2", "title": "Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8216, "first_name": "Richard A", "last_name": "Jenkins", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-05-15", "end_date": "2022-02-28", "award_amount": 152199, "principal_investigator": { "id": 9820, "first_name": "CAREY", "last_name": "FARQUHAR", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22826, "first_name": "Joshua T", "last_name": "Herbeck", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "In sub-Saharan Africa and globally, many persons who inject drugs (PWID) are living with undiagnosed or untreated HIV, experience high levels of poverty, food and housing instability, and discrimination, and have increased risk for health conditions that contribute to worse outcomes from COVID-19. It is also more challenging for PWID to access healthcare when services have been limited by lockdowns and measures to ensure social distancing to prevent spread of respiratory viruses, such as SARS-CoV-2. We propose to recruit and follow a cohort of 500 HIV-positive and 500 HIV-negative PWID and their partners, many of whom also have hepatitis C, to determine whether poorly controlled HIV infection, active drug use and other HIV- and PWID-specific risk factors result in increased likelihood of COVID-19 acquisition, viral transmission, symptomatic disease and poor clinical outcomes (AIM 1). We will also define transmission dynamics through phylogenetic analyses of SAR-CoV-2 sequences from symptomatic PWID (AIM 2) and determine whether HIV care and harm reduction service delivery disruptions are associated with poor compliance to ART and methadone, HIV viremia and other adverse outcomes (AIM 3). Our proposal is innovative in how it reaches PWID and partners using peer educators, employs targeted testing and symptom screening in this high-risk Kenyan population, and defines COVID-19 transmission within and beyond local networks using phylogenetics. Participant recruitment and enrollment will take place in drop-in centers and methadone clinics in Nairobi, Mombasa and Kilifi, Kenya and follow-up visits will occur monthly for 6 months. In addition to collecting interview data and blood for SARS- CoV-2 antibodies, we will ask participants who have symptoms consistent with COVID-19 at any of the 7 visits to self-collect a nasal swab specimen for SARS-CoV-2 polymerase chain reaction (PCR), followed by genome sequencing if positive. Laboratory assays for antibody and viral PCR testing will be conducted in Nairobi and positive specimens will be shipped to Seattle for sequencing and phylogenetic analysis. We anticipate that our results will highlight the need for targeted testing among PWID and inform interventions and programs for HIV and addiction care and treatment across the globe for similar marginalized populations when confronted with COVID-19 and other public health crises.", "keywords": [ "2019-nCoV", "Address", "Adherence", "Africa South of the Sahara", "African", "Antibodies", "Award", "Behavior", "Biological Assay", "Blood", "COVID-19", "COVID-19 pandemic", "Cardiovascular Diseases", "Caring", "Cessation of life", "Clinical", "Communities", "Country", "Data", "Discrimination", "Disease", "Drops", "Drug usage", "Economics", "Enrollment", "Ensure", "Food", "General Population", "Government", "HIV", "HIV Infections", "HIV Seronegativity", "HIV Seropositivity", "HIV risk", "HIV/HCV", "Harm Reduction", "Health", "Health Services Accessibility", "Healthcare Systems", "Hepatitis C", "Hepatitis C Viremia", "Hot Spot", "Individual", "Infection", "Injecting drug user", "Interview", "Kenya", "Laboratories", "Lung diseases", "Measures", "Methadone", "Morbidity - disease rate", "Natural History", "Needles", "Nose", "Outcome", "Parents", "Participant", "Patient Recruitments", "Pattern", "Personal Satisfaction", "Pharmaceutical Preparations", "Phylogenetic Analysis", "Polymerase Chain Reaction", "Population", "Population Control", "Population Density", "Poverty", "Prevalence", "Prevention", "Public Health", "Reporting", "Research", "Research Infrastructure", "Risk", "Risk Factors", "Sampling", "Services", "Ships", "Site", "Social Distance", "Social Network", "Specimen", "Swab", "Symptoms", "Syringes", "Target Populations", "Testing", "Time", "Viral", "Viremia", "Virus", "Visit", "Vulnerable Populations", "Woman", "addiction", "adverse outcome", "antiretroviral therapy", "base", "clinical care", "cohort", "comorbidity", "experience", "follow-up", "genome sequencing", "health care availability", "health care service", "high risk", "housing instability", "improved", "infection rate", "injection drug use", "innovation", "intervention program", "men", "methadone clinic/center", "mortality", "pandemic disease", "peer", "prevent", "recruit", "respiratory virus", "response", "screening", "seropositive", "service delivery", "social", "social stigma", "socioeconomics", "study population", "transmission process", "uptake", "viral transmission" ], "approved": true } }, { "type": "Grant", "id": "7044", "attributes": { "award_id": "3UL1TR002538-03S3", "title": "Infrastructure Support for Participation in the N3C Data Repository", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22830, "first_name": "Andrew", "last_name": "Louden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-08-15", "end_date": "2023-02-28", "award_amount": 99056, "principal_investigator": { "id": 22831, "first_name": "WILLARD H.", "last_name": "DERE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22832, "first_name": "RACHEL", "last_name": "HESS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "- OVERALL The University of Utah Center for Clinical and Translational Science (CCTS) serves as the central locus of translational research in the Intermountain West. The CCTS has become the center for combining the efforts of the University of Utah and its partners into a vibrant research enterprise which advances both clinical projects and the science of translational research. To realize these goals, the CCTS is led by Co-Principal Investigators Drs. Dere and Hess, who are well positioned within institutional leadership and are supported by a variety of institutional initiatives and resources that complement the CCTS activities. The Co-PIs are supported by an integrated group of experienced local, regional, and national leaders and are guided by a comprehensive oversight structure that anchors the CCTS within the University of Utah and its partners. Our proposal builds on a firm foundation of achievements in areas of strength which include but are not limited to: our genetics programs, which has led to discoveries of numerous disease-causing genes and to a variety of software platforms that are used in computational genomics globally; our community-outreach efforts, highlighted by state- and nationwide initiatives by key leaders; our statistical methods and software developed to evaluate surrogate markers; and our substantive experiences in clinical trials, both traditional randomized and pragmatic, and multi-center collaboration networks, which continue to study a variety of special populations identified by the recent NCATS Lifespan initiatives. By supporting successful trainees at all levels and preparing them for productive careers, we are building a diverse workforce able to use our extensive infrastructure to advance national CTSA goals. The breadth of the CCTS activities allows it to address established and emerging institutional issues by providing timely resources, advice, and services. We look forward to addressing major public health and translational research issues through a comprehensive suite of services, as well as a culture that prizes team science and high quality research in order to better ensure research reproducibility. We seek to achieve our goals through four specific aims: (1) Catalyze clinical and translational research as the CTSA hub for the Intermountain West; (2) Advance and refine an educational environment that maximizes the value of collaboration and training among various stakeholders; (3) Integrate diverse partners for meaningful collaborations in research endeavors across the translational spectrum; (4) Promote efficient and effective data collection, analyses, and sharing that leverages innovative informatics- based solutions.", "keywords": [ "Achievement", "Address", "Area", "Clinical", "Clinical Research", "Clinical Sciences", "Clinical Trials", "Collaborations", "Community Outreach", "Complement", "Computer software", "Data", "Data Collection", "Development", "Disease", "Diverse Workforce", "Ensure", "Foundations", "Funding", "Genes", "Genetic", "Genomics", "Goals", "Informatics", "Infrastructure", "Leadership", "Longevity", "Methods", "Patients", "Population", "Positioning Attribute", "Principal Investigator", "Prize", "Public Health", "Randomized", "Records", "Reproducibility", "Research", "Resources", "Rural", "Science", "Services", "Statistical Methods", "Structure", "Surrogate Markers", "Time", "Training", "Translational Research", "Universities", "Utah", "base", "career", "clinical center", "cohort", "coronavirus disease", "data warehouse", "doctoral student", "educational atmosphere", "experience", "frontier", "innovation", "named group", "parent grant", "programs", "software development", "translational pipeline" ], "approved": true } }, { "type": "Grant", "id": "9249", "attributes": { "award_id": "3UL1TR002538-03S4", "title": "Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 22830, "first_name": "Andrew", "last_name": "Louden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-23", "end_date": "2023-02-28", "award_amount": 3762086, "principal_investigator": { "id": 22614, "first_name": "GUILHERME", "last_name": "DEL FIOL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 21047, "first_name": "David W", "last_name": "Wetter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true } ] }, { "id": 22832, "first_name": "RACHEL", "last_name": "HESS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 202, "ror": "https://ror.org/03r0ha626", "name": "University of Utah", "address": "", "city": "", "state": "UT", "zip": "", "country": "United States", "approved": true }, "abstract": "Racial/ethnic minority, low socioeconomic status (SES), and rural populations suffer profound health inequities across a wide variety of diseases and conditions, as well as a disproportionate burden of the negative health consequences of the COVID-19 pandemic. Latinos make up ~14% of the Utah population vs. ~40% of Utah's COVID-19 cases, and the case rate is over 3-fold higher in neighborhoods characterized by high vs. low deprivation. The case rate in Utah per 100,000 is 665 among Whites vs. 3,503 among Latinos, 3,470 among Pacific Islanders, 1,727 among African Americans, and 1,569 among Native Americans. Community Health Centers (CHCs) are optimal settings for addressing the screening and uptake of COVID-19 testing among underserved populations. Twelve Utah CHC systems are participating in SCALE-UP Utah. Their 39 primary care clinics serve over 115,000 unique patients annually (37% Latino, 11% Native American, 61% <100% poverty level, 51% uninsured, and 49% of clinics are in rural/frontier areas). SCALE-UP Utah is a state-wide, pragmatic, multilevel intervention study. The long-term objective is to increase the reach, uptake, and sustainability of COVID-19 screening and testing among underserved populations. The team has existing infrastructure and “shovel ready” clinic and population health management (PHM) interventions ready for implementation. SCALE-UP Utah builds on long standing, funded partnerships, and will implement and evaluate three practical, feasible, scalable multi-level interventions to increase COVID-19 screening and uptake in Utah CHCs. Interventions leverage widely adopted Health Information Technology (HIT) at the point of care, text messaging, and patient navigation. SCALE-UP Utah will coordinate and synergize existing infrastructure and resources across the state, as well as strengthen infrastructure and data networks for rapid deployment of new screening and testing protocols, vaccination programs, etc. The project will employ a rapid cycle research approach in which interventions are tested on a small scale, using short time frames (e.g., <1 month) and cyclical evaluation cycles. A critical aspect of these rapid-research cycles is that change can be quickly tested on a small scale, and then disseminated to other clinics/patients. The interventions will be readily available for adoption by other low-resource healthcare settings; and, the data will advance population health and implementation science. The specific aims are to: 1. Implement and evaluate clinic and PHM interventions for increasing the uptake of COVID-19 testing among CHC patients across Utah. 2. Examine implementation effectiveness outcomes, as well as characteristics of both clinics and patients that may influence intervention effects and implementation outcomes.", "keywords": [ "Address", "Adopted", "Adoption", "African American", "Area", "Behavior", "COVID-19", "COVID-19 pandemic", "Characteristics", "Clinic", "Clinical", "Clinical Sciences", "Communities", "Community Health", "Data", "Data Analytics", "Disease", "Effectiveness", "Electronic Health Record", "Evaluation", "Evidence based intervention", "Funding", "Guidelines", "Health", "Health Sciences", "Health Status", "Healthcare Systems", "Infection", "Infrastructure", "Intervention", "Intervention Studies", "Latino", "Logistics", "Native Americans", "Neighborhood Health Center", "Neighborhoods", "Outcome", "Outpatients", "Pacific Island Americans", "Patients", "Periodicity", "Population", "Poverty", "Preventive", "Primary Health Care", "Procedures", "Process", "Protocols documentation", "Quick Test for Liver Function", "Research", "Resources", "Rural", "Rural Population", "Support System", "System", "Testing", "Text Messaging", "Time", "Translational Research", "Underserved Population", "Uninsured", "Universities", "Update", "Utah", "Vaccination", "base", "clinical center", "deprivation", "digital", "ethnic minority population", "experience", "frontier", "health care settings", "health information technology", "health management", "high risk", "implementation science", "improved", "intervention effect", "low socioeconomic status", "patient engagement", "patient oriented", "patient population", "point of care", "population health", "primary outcome", "programs", "racial and ethnic", "scale up", "screening", "standard of care", "uptake" ], "approved": true } }, { "type": "Grant", "id": "7045", "attributes": { "award_id": "3UG3TR003081-01S1", "title": "Drug-drug interactions for antivirals with opioids and Narcan in a 5- organ human-on-a-chip model", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 22833, "first_name": "Danilo A.", "last_name": "Tagle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-27", "end_date": "2021-07-31", "award_amount": 167033, "principal_investigator": { "id": 22834, "first_name": "James J", "last_name": "Hickman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1475, "ror": "https://ror.org/036nfer12", "name": "University of Central Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22835, "first_name": "MICHAEL L", "last_name": "SHULER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1475, "ror": "https://ror.org/036nfer12", "name": "University of Central Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Addiction to pain medications, especially opiates, has become a major health problem and systems to guide the understanding of repeat overdose treatments are needed. Our proposal seeks to build overdose models for four drugs (fentanyl, methadone, codeine, and morphine) in a multi-organ system and evaluate the acute and repeat dose, or chronic effects, of overdose treatments such as Naloxone on overdose recovery, efficacy as well as off-target toxicity for cardiac, muscle, kidney and liver. We have developed a low cost system using human cells in a pumpless multi-organ platform that allows continuous recirculation of a blood surrogate for up to 28 days. This system emulates the distribution of a parental compound and the formation of metabolites among all “organ” compartments and predicts potential toxicity and efficacy of drugs better than in vitro single human organ or animal models. We will develop two different overdose models for both male and female phenotypes based on nociceptors and Bӧtzinger Complex (BӧtC) neurons as they contain µ-opioid receptors but are thought to have different roles in response to overdose and treatment. We will also integrate functional immune components in the UH3 Phase that has been demonstrated to enable organ specific or systemic monocyte actuation. In addition, models for cardiomyopathy and an infection model will be utilized to more accurately represent the effects of therapeutics on comorbidities. We will establish a PKPD in vitro model of overdose and treatment to enable prediction in clinical environments for a range of variables including age and drug-drug interactions. Once established the system could be used to evaluate novel pain therapeutics for efficacy and off-target toxicity as well as additional overdose treatments in future studies. Interconnected systems with continuous recirculation of a blood surrogate allows both the parent compound and its metabolites to be evaluated in the same system since it is a low volume platform. This interconnected system is better suited for preclinical drug testing than single organ systems for the same reason that human and animal models are currently the gold standards for toxicity and efficacy determination as they allow communication between the organ systems in the body. To construct a well defined system we will use a common serum free medium with microelectrode arrays and cantilever systems that are integrated on chip that allow for noninvasive electronic and mechanical readouts of organ function. UCF and Hesperos in collaboration with clinicians seek to radically change established practice in drug discovery by bypassing animal experiments and extensive clinical trials to provide treatments for diseases and clinical conditions such as overdose. We have already been working with regulatory authorities to prepare for eventual acceptance of the systems for regular use in INDs. Since Hesperos is already offering multi-organ evaluations as a service to the pharmaceutical industry and clinicians there is a direct translational element in the proposal.", "keywords": [ "Acute", "Age", "Analgesics", "Animal Experiments", "Animal Model", "Antiviral Agents", "Blood", "Brain Stem", "Breathing", "Bypass", "Cardiac", "Cardiac Myocytes", "Cardiomyopathies", "Cardiotoxicity", "Cells", "Cellular Structures", "Cessation of life", "Chronic", "Clinic", "Clinical", "Clinical Trials", "Codeine", "Collaborations", "Communication", "Community Developments", "Complex", "Development", "Disease", "Disease model", "Dose", "Drug Industry", "Drug Interactions", "Elements", "Environment", "Evaluation", "Female", "Fentanyl", "Functional disorder", "Funding", "Future", "Goals", "Gold", "Grant", "Health", "Heart Diseases", "Human", "Immune", "Immunological Models", "In Vitro", "Infection", "Kidney", "Lead", "Legal patent", "Liver", "Long-Term Effects", "Mechanics", "Methadone", "Microelectrodes", "Modeling", "Morphine", "Muscle", "Myocardium", "Naloxone", "Narcan", "Neurons", "Nociceptors", "Opioid", "Opioid abuser", "Organ", "Organ Model", "Organ failure", "Outcome", "Overdose", "Pain", "Parents", "Patients", "Pharmaceutical Preparations", "Phase", "Phenotype", "Physicians", "Physiology", "Pre-Clinical Model", "Publishing", "Recovery", "Role", "Serum", "Services", "Skeletal Muscle", "System", "Therapeutic", "Therapeutic Effect", "Tissue Microarray", "Tissue Model", "Toxic effect", "Translating", "Translations", "Treatment Efficacy", "addiction", "authority", "base", "body system", "cantilever", "clinical predictors", "comorbidity", "cooking", "cost", "drug candidate", "drug development", "drug discovery", "drug efficacy", "drug testing", "human model", "in vitro Model", "individualized medicine", "male", "model development", "monocyte", "mu opioid receptors", "novel", "opioid overdose", "personalized medicine", "pharmacokinetics and pharmacodynamics", "physiologically based pharmacokinetics", "pre-clinical", "preclinical study", "response", "screening", "skills", "success" ], "approved": true } }, { "type": "Grant", "id": "7046", "attributes": { "award_id": "3R01AA021746-05S1", "title": "Next Generation Rare Variant Discovery in Multiplex AD Families", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Alcohol Abuse and Alcoholism (NIAAA)" ], "program_reference_codes": [], "program_officials": [ { "id": 20732, "first_name": "Abbas", "last_name": "Parsian", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-09-01", "end_date": "2022-05-31", "award_amount": 156267, "principal_investigator": { "id": 22836, "first_name": "David B.", "last_name": "Goldstein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22837, "first_name": "SHIRLEY", "last_name": "HILL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The World Health Organization (WHO) is currently reporting 4,793,076 confirmed cases of COVID-19 infection world-wide with 316,341 deaths. With each new pandemic the population is at risk until vaccines and medications can be developed. Quarantine of the entire population appears to be only alternative until sufficient time elapses for vaccine development. Therefore, an important public health goal is to determine who must be sheltered in place and who can resume normal activities. Older individuals appear to be disproportionately adversely affected by the virus. Although immune functioning tends to wane with age, genetic and lifestyle factors appear to greatly alter susceptibility. The goal of this project is to identify individuals who may be more or less resilient due to their lifetime use of alcohol. Those with an alcohol use disorder (AUD) may have a greater risk for adverse consequences of SARS-CoV-2 exposure, yet low dose consumption may improve immune functioning. A better understanding of whether alcohol use has a different effect at low doses than at high doses is critical to public health campaigns that advise the public on safe use of alcohol. Genetic variation in the Major Histocompatiblity Locus (MHC) located on chromosome 6 plays an important role in immune functioning. Variation in the human leucocyte antigens (HLA) have been significantly associated with many diseases and hold promise for personalized antigen-specific disease prevention. Having this information available, as part of routine medical screening in the future, would enable us to stratify the population into those needing sheltering in place and those who do not. This project would determine the feasibility of using HLA gene variation along with screening for alcohol use as an important part of stratifying the population at the onset of viral epidemics. The present proposal builds on existing resources from participants for whom exome sequencing and/or HLA serology was completed and utilizes the extensive alcohol use histories, psychiatric diagnoses, and health histories obtained at baseline. New interviews concerning alcohol use, both distal and proximal, current health status, and exposure histories for the SARS- CoV-2 virus will enable us to determine their contribution to infection and progression. We will contrast those with AUD with those without and unaffected members of high risk versus low risk families in (Aim 1). In Aim 2, we will assess levels of recent and past alcohol consumption to viral response. Genetic variation in the major histocompatibility complex (HLA) region will be tested for association with outcome among those that are demonstrated to have been exposed (Aim 3).", "keywords": [ "2019-nCoV", "Acute", "Affect", "Age", "Alcohol consumption", "Alcohols", "Antigenic Variation", "Antigens", "Award", "Beer", "Beverages", "COVID-19", "COVID-19 pandemic", "Cessation of life", "Characteristics", "Chromosome 6", "Cigarette", "Clinical", "Common Cold", "Complex", "Consensus", "Consumption", "Contracts", "Data", "Demographic Factors", "Diabetes Mellitus", "Diagnosis", "Disease", "Distal", "Dose", "Drug usage", "Epidemic", "Ethnic Origin", "Exposure to", "Family", "Frequencies", "Future", "Genes", "Genetic", "Genetic Variation", "Goals", "HLA Antigens", "Health", "Health Campaign", "Health Status", "Heavy Drinking", "Heritability", "Human", "Hypertension", "Immune response", "Immunity", "Incidence", "Individual", "Infection", "Infectious Mononucleosis", "Interview", "Major Histocompatibility Complex", "Mediating", "Medical", "Morbidity - disease rate", "New York", "Obesity", "Outcome", "Participant", "Pharmaceutical Preparations", "Play", "Population", "Predisposition", "Production", "Psychiatric Diagnosis", "Public Health", "Quarantine", "Recording of previous events", "Recovery", "Reporting", "Research", "Resources", "Risk", "Role", "SARS coronavirus", "Serologic tests", "Shelter facility", "Symptoms", "T-Lymphocyte", "Taiwan", "Testing", "Time", "Vaccines", "Variant", "Viral", "Virus", "Virus Diseases", "Wine", "World Health Organization", "adverse outcome", "alcohol effect", "alcohol measurement", "alcohol misuse", "alcohol risk", "alcohol screening", "alcohol use disorder", "comorbidity", "cytokine", "disorder prevention", "drinking", "exome sequencing", "experience", "health goals", "high risk", "immune function", "improved", "lifestyle factors", "medical attention", "member", "mortality", "mortality statistics", "next generation", "pandemic disease", "programs", "psychiatric symptom", "rare variant", "respiratory", "respiratory virus", "response", "screening", "sex", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "7047", "attributes": { "award_id": "3R43MD014916-01S1", "title": "Digital contact tracing and case investigation application on the Navajo Nation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 22838, "first_name": "SIMRANN KAUR", "last_name": "Sidhu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-09-24", "end_date": "2021-06-30", "award_amount": 181240, "principal_investigator": { "id": 22839, "first_name": "Y. Xian XIAN", "last_name": "Ho", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1543, "ror": "", "name": "DIMAGI, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22840, "first_name": "Jonathan Lee", "last_name": "Jackson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1543, "ror": "", "name": "DIMAGI, INC.", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has had a disproportionate effect on the Navajo Nation, in which there is a higher prevalence of health complications such as diabetes, heart and lung disease. Overall living conditions and a long history of inequities resulting in a distrust of western medicine and health systems are believed to contribute to the spread of the virus. This project is an urgent competitive revision to an existing project in response to PA- 18-935. The project supplements an ongoing SBIR Phase I project to study the feasibility and acceptability of COPECare, a novel digital system to support care coordination on the Navajo Nation, particularly those who have or are at high risk of cancer. COPECare is designed to facilitate the work of community health representatives (CHRs) who play a critical role in delivering health education and guidance to members of the Navajo Nation. Since the outbreak of COVID-19 on the Navajo Nation, CHRs and other trained and lay workers have been tasked to support contact tracing efforts throughout the community using a digital contact tracing and case investigation tool. The goal of this urgent supplement is to study the process and early outcomes of a digital contact tracing and case investigation tool that was customized for use on the Navajo Nation and rapidly deployed to support efforts to manage and control the COVID-19 outbreak. We will address this goal in the following two specific aims: In Aim 1, we will evaluate the digital tool using key metrics to gauge program performance for case interviewing and measures of system efficiency. In Aim 2, we will conduct a formative assessment consisting of qualitative one-on-one and group interviews with cadres of contact tracers (CHRs, public health officials, and hospital staff at two large hospitals serving the Navajo Nation) and cancer survivors and their families directly or indirectly affected by COVID-19. Results of this supplement work will directly inform the design and development of COPECare and contribute to a broader understanding of how to develop effective community-based digital solutions to support and promote health on Navajo Nation and potentially other tribal communities across the US.", "keywords": [ "Address", "Adoption", "Affect", "Behavioral", "Biological", "COVID-19", "COVID-19 pandemic", "Cancer Patient", "Cancer Survivor", "Case Management", "Communicable Diseases", "Communities", "Community Health", "Contact Tracing", "Containment", "Coronavirus Infections", "Custom", "Development", "Diabetes Mellitus", "Disease Outbreaks", "Epidemiology", "Exposure to", "Family", "Feasibility Studies", "Feedback", "Goals", "Government", "Group Interviews", "Health", "Health Food", "Health Promotion", "Health education", "Health system", "Heart Diseases", "High Prevalence", "High-Risk Cancer", "Hospitals", "Hot Spot", "Household and Family", "Individual", "Intervention", "Interview", "Interviewer", "Investigation", "Learning", "Lung diseases", "Malignant Neoplasms", "Measures", "Medicine", "Modeling", "Native Americans", "Navajo", "New York", "Notification", "Outcome", "Participant", "Patients", "Performance", "Phase", "Play", "Policies", "Population", "Process", "Protocols documentation", "Public Health", "Public Health Education", "Recording of previous events", "Reporting", "Research", "Risk", "Role", "Small Business Innovation Research Grant", "Structure", "Support System", "System", "Techniques", "Technology", "Time", "Tracer", "Training", "Virus", "Water", "Work", "acute care", "base", "care coordination", "cost", "design", "digital", "experience", "follow-up", "formative assessment", "health disparity", "health service use", "infection rate", "member", "novel", "outreach", "pandemic disease", "programs", "resilience", "response", "surveillance data", "tool", "tribal community", "underserved minority", "uptake" ], "approved": true } }, { "type": "Grant", "id": "7052", "attributes": { "award_id": "3R01AI128775-07S1", "title": "COVID R PA-18-591 NOT-AI-20-031 Administrative Supplement to Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22844, "first_name": "MONICA", "last_name": "Zamisch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-13", "end_date": "2022-02-28", "award_amount": 256339, "principal_investigator": { "id": 10671, "first_name": "JILL Allison", "last_name": "HOLLENBACH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22845, "first_name": "STEVEN JOHN", "last_name": "MACK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "- Supplement While little is known about the impact of host genetic factors on the risk for infection, morbidity and mortality in COVID-19, current epidemiology reveals wide variation in disease course among confirmed cases of infection that is not fully explained by known comorbidities and other risk factors. Because of its pivotal role in the immune response and long-established associations with disease phenotypes, Human Leukocyte Antigen (HLA) variation will likely be found to play a key role in COVID-19 outcomes. Understanding the role of HLA variation will provide important insights relevant to the immunopathogenesis of COVID-19, while also informing vaccine development and potential immunotherapies (e.g. T-cell based therapies). Because the complexity and extreme polymorphism of the HLA region make consolidation, equivalency, analysis, and biological interpretation of HLA data challenging, it is our view that a centralized resource that aggregates data from disparate sources and platforms and provides well-curated bioinformatics and analytical tools will serve to accelerate discovery. Under the parent grant we continue to develop a suite of tools and programs for the standardized analysis, collection, exchange and storage of immunogenetic data, and these tools are being widely adopted by the immunogenetics community. This supplement request will allow us to apply these tools toward the development and application of a pair of web resources. The first will centralize access to COVID-19-related HLA data and HLA data- management and analysis tools, creating a knowledge base and technical resource for HLA and immunogenetics research on the COVID-19 pandemic. As an initial step in advancing this vision, we have launched the hlacovid19.org website. The second resource will connect COVID-19 researchers and clinicians in need of HLA typing services with the immunogenetics laboratories that can provide them. As an early step toward this goal, we have formed the COVID-19 HLA & Immunogenetics Consortium to unite the global community of HLA and immunogenetics experts and leaders in support of these efforts, and harness the collective experience and expertise of the HLA and immunogenetics community as part of the global effort to combat this pandemic.", "keywords": [ "Accreditation", "Address", "Administrative Supplement", "Adopted", "Alleles", "Antigenic Variation", "Base Sequence", "Biological", "Bone Marrow", "COVID-19", "COVID-19 pandemic", "Clinical Data", "Collection", "Communities", "Country", "Data", "Data Aggregation", "Data Analyses", "Data Collection", "Data Scientist", "Data Set", "Development", "Directories", "Disease", "Epidemiology", "Future Generations", "Genes", "Genetic", "Genetic Polymorphism", "Genomics", "Genotype", "Goals", "HLA Antigens", "Haplotypes", "Health", "Human", "Human Genome", "Human Resources", "Immune response", "Immunogenetics", "Immunogenomics", "Immunotherapy", "Infection", "International", "Journals", "Laboratories", "Libraries", "Link", "Literature", "Methods", "Morbidity - disease rate", "Online Systems", "Organ Transplantation", "Outcome", "Patients", "Play", "Publishing", "Research", "Research Personnel", "Resolution", "Resources", "Rest", "Risk Factors", "Role", "Services", "Software Tools", "Solid", "Source", "Specimen", "Standardization", "System", "T cell therapy", "Vaccines", "Variant", "Vision", "analytical tool", "base", "bioinformatics tool", "central database", "combat", "comorbidity", "coronavirus disease", "data management", "data tools", "disease phenotype", "exome sequencing", "experience", "human leukocyte antigen testing", "improved", "infection risk", "insight", "knowledge base", "member", "mortality", "next generation", "online resource", "pandemic disease", "parent grant", "programs", "quality assurance", "tool", "vaccine development", "web site", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "7055", "attributes": { "award_id": "3R01DA042755-04S1", "title": "Impact of Marijuana Legalization: Comparison of Two Longitudinal Twin Cohorts", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8355, "first_name": "HEATHER L", "last_name": "KIMMEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-01", "end_date": "2022-05-31", "award_amount": 154303, "principal_investigator": { "id": 22848, "first_name": "JOHN K.", "last_name": "HEWITT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22849, "first_name": "Christian J", "last_name": "Hopfer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22850, "first_name": "MATTHEW K.", "last_name": "MCGUE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22851, "first_name": "Scott Ian", "last_name": "Vrieze", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "This supplemental grant proposes to add questions to extend the aims of the parent project by collecting additional data related to COVID-19 including financial hardships, social/interpersonal problems, stress, mental health, and substance use changes. Data will also be collected on whether participants are essential workers, were exposed to COVID-19, or have been diagnosed with COVID-19. Parent grant Aim 1: Effect of RML on substance use/misuse, mental health, & psychosocial function Aim 1 extended: Effect of COVID-19 pandemic and RML on substance use/misuse, mental health & psychosocial function. We will test the hypothesis that access to RML increases the likelihood that the stress and disruption associated with COVID-19 will lead to increased marijuana use and abuse. Relatedly, we will test the extent to which increased marijuana use, related to RML and stress/disruptions from COVID-19, is accompanied by increases in other substance use, mental health disorders, or psychosocial dysfunction. Parent grant Aim 2: Individual differences in the effect of RML Aim 2 extended: Examine individual differences in the effect of COVID-19 pandemic and RML. Examine individual differences in the effects of COVID-19 and legalization by leveraging parallel multi-wave longitudinal twin studies in CO and MN, which both began collecting substance use, psychopathology, and psychosocial function during the twins' adolescence. This supplemental assessment will allow us to: a) identify how COVID-19 differentially impacts individuals depending on legalization and prior exposure to marijuana; b) examine how individuals differ in their vulnerability and resilience to the effects COVID-19, in the context of legalization, based on their individual level of risk (e.g., prior diagnosis of anxiety or depression); and c) examine if there are differential associations between COVID-19 and substance use/dependence, mental health, and psychosocial problems depending on legalization status and gender.", "keywords": [ "Adolescence", "Adult", "Affect", "Age", "Alcohol consumption", "Alcohol or Other Drugs use", "Alcohols", "Anxiety", "Behavior", "COVID-19", "COVID-19 pandemic", "Cannabis", "Cessation of life", "China", "Colorado", "Data", "Dependence", "Diagnosis", "Disease", "Exposure to", "Financial Hardship", "Functional disorder", "Gender", "Goals", "Grant", "Home environment", "Individual", "Individual Differences", "International", "Legal", "Legal Status", "Marijuana", "Marijuana Abuse", "Market Research", "Measurement", "Medical Marijuana", "Mental Depression", "Mental Health", "Mental disorders", "Minnesota", "Occupational", "Participant", "Pattern", "Property", "Psychopathology", "Reporting", "Research", "Risk", "Sales", "Sample Size", "Sampling", "Social Distance", "Stress", "Substance Addiction", "Substance Use Disorder", "Testing", "Time", "Twin Multiple Birth", "Twin Studies", "Unemployment", "United States", "World Health Organization", "base", "behavioral disinhibition", "cohort", "coronavirus disease", "drinking", "drinking behavior", "marijuana legalization", "marijuana use", "novel virus", "parent grant", "parent project", "psychosocial", "public health emergency", "resilience", "social", "stressor", "substance misuse" ], "approved": true } }, { "type": "Grant", "id": "7055", "attributes": { "award_id": "3R01DA042755-04S1", "title": "Impact of Marijuana Legalization: Comparison of Two Longitudinal Twin Cohorts", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8355, "first_name": "HEATHER L", "last_name": "KIMMEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-01", "end_date": "2022-05-31", "award_amount": 154303, "principal_investigator": { "id": 22848, "first_name": "JOHN K.", "last_name": "HEWITT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22849, "first_name": "Christian J", "last_name": "Hopfer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22850, "first_name": "MATTHEW K.", "last_name": "MCGUE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22851, "first_name": "Scott Ian", "last_name": "Vrieze", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "This supplemental grant proposes to add questions to extend the aims of the parent project by collecting additional data related to COVID-19 including financial hardships, social/interpersonal problems, stress, mental health, and substance use changes. Data will also be collected on whether participants are essential workers, were exposed to COVID-19, or have been diagnosed with COVID-19. Parent grant Aim 1: Effect of RML on substance use/misuse, mental health, & psychosocial function Aim 1 extended: Effect of COVID-19 pandemic and RML on substance use/misuse, mental health & psychosocial function. We will test the hypothesis that access to RML increases the likelihood that the stress and disruption associated with COVID-19 will lead to increased marijuana use and abuse. Relatedly, we will test the extent to which increased marijuana use, related to RML and stress/disruptions from COVID-19, is accompanied by increases in other substance use, mental health disorders, or psychosocial dysfunction. Parent grant Aim 2: Individual differences in the effect of RML Aim 2 extended: Examine individual differences in the effect of COVID-19 pandemic and RML. Examine individual differences in the effects of COVID-19 and legalization by leveraging parallel multi-wave longitudinal twin studies in CO and MN, which both began collecting substance use, psychopathology, and psychosocial function during the twins' adolescence. This supplemental assessment will allow us to: a) identify how COVID-19 differentially impacts individuals depending on legalization and prior exposure to marijuana; b) examine how individuals differ in their vulnerability and resilience to the effects COVID-19, in the context of legalization, based on their individual level of risk (e.g., prior diagnosis of anxiety or depression); and c) examine if there are differential associations between COVID-19 and substance use/dependence, mental health, and psychosocial problems depending on legalization status and gender.", "keywords": [ "Adolescence", "Adult", "Affect", "Age", "Alcohol consumption", "Alcohol or Other Drugs use", "Alcohols", "Anxiety", "Behavior", "COVID-19", "COVID-19 pandemic", "Cannabis", "Cessation of life", "China", "Colorado", "Data", "Dependence", "Diagnosis", "Disease", "Exposure to", "Financial Hardship", "Functional disorder", "Gender", "Goals", "Grant", "Home environment", "Individual", "Individual Differences", "International", "Legal", "Legal Status", "Marijuana", "Marijuana Abuse", "Market Research", "Measurement", "Medical Marijuana", "Mental Depression", "Mental Health", "Mental disorders", "Minnesota", "Occupational", "Participant", "Pattern", "Property", "Psychopathology", "Reporting", "Research", "Risk", "Sales", "Sample Size", "Sampling", "Social Distance", "Stress", "Substance Addiction", "Substance Use Disorder", "Testing", "Time", "Twin Multiple Birth", "Twin Studies", "Unemployment", "United States", "World Health Organization", "base", "behavioral disinhibition", "cohort", "coronavirus disease", "drinking", "drinking behavior", "marijuana legalization", "marijuana use", "novel virus", "parent grant", "parent project", "psychosocial", "public health emergency", "resilience", "social", "stressor", "substance misuse" ], "approved": true } }, { "type": "Grant", "id": "7055", "attributes": { "award_id": "3R01DA042755-04S1", "title": "Impact of Marijuana Legalization: Comparison of Two Longitudinal Twin Cohorts", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8355, "first_name": "HEATHER L", "last_name": "KIMMEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-01", "end_date": "2022-05-31", "award_amount": 154303, "principal_investigator": { "id": 22848, "first_name": "JOHN K.", "last_name": "HEWITT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22849, "first_name": "Christian J", "last_name": "Hopfer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22850, "first_name": "MATTHEW K.", "last_name": "MCGUE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 22851, "first_name": "Scott Ian", "last_name": "Vrieze", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 784, "ror": "https://ror.org/02hh7en24", "name": "University of Colorado Denver", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "This supplemental grant proposes to add questions to extend the aims of the parent project by collecting additional data related to COVID-19 including financial hardships, social/interpersonal problems, stress, mental health, and substance use changes. Data will also be collected on whether participants are essential workers, were exposed to COVID-19, or have been diagnosed with COVID-19. Parent grant Aim 1: Effect of RML on substance use/misuse, mental health, & psychosocial function Aim 1 extended: Effect of COVID-19 pandemic and RML on substance use/misuse, mental health & psychosocial function. We will test the hypothesis that access to RML increases the likelihood that the stress and disruption associated with COVID-19 will lead to increased marijuana use and abuse. Relatedly, we will test the extent to which increased marijuana use, related to RML and stress/disruptions from COVID-19, is accompanied by increases in other substance use, mental health disorders, or psychosocial dysfunction. Parent grant Aim 2: Individual differences in the effect of RML Aim 2 extended: Examine individual differences in the effect of COVID-19 pandemic and RML. Examine individual differences in the effects of COVID-19 and legalization by leveraging parallel multi-wave longitudinal twin studies in CO and MN, which both began collecting substance use, psychopathology, and psychosocial function during the twins' adolescence. This supplemental assessment will allow us to: a) identify how COVID-19 differentially impacts individuals depending on legalization and prior exposure to marijuana; b) examine how individuals differ in their vulnerability and resilience to the effects COVID-19, in the context of legalization, based on their individual level of risk (e.g., prior diagnosis of anxiety or depression); and c) examine if there are differential associations between COVID-19 and substance use/dependence, mental health, and psychosocial problems depending on legalization status and gender.", "keywords": [ "Adolescence", "Adult", "Affect", "Age", "Alcohol consumption", "Alcohol or Other Drugs use", "Alcohols", "Anxiety", "Behavior", "COVID-19", "COVID-19 pandemic", "Cannabis", "Cessation of life", "China", "Colorado", "Data", "Dependence", "Diagnosis", "Disease", "Exposure to", "Financial Hardship", "Functional disorder", "Gender", "Goals", "Grant", "Home environment", "Individual", "Individual Differences", "International", "Legal", "Legal Status", "Marijuana", "Marijuana Abuse", "Market Research", "Measurement", "Medical Marijuana", "Mental Depression", "Mental Health", "Mental disorders", "Minnesota", "Occupational", "Participant", "Pattern", "Property", "Psychopathology", "Reporting", "Research", "Risk", "Sales", "Sample Size", "Sampling", "Social Distance", "Stress", "Substance Addiction", "Substance Use Disorder", "Testing", "Time", "Twin Multiple Birth", "Twin Studies", "Unemployment", "United States", "World Health Organization", "base", "behavioral disinhibition", "cohort", "coronavirus disease", "drinking", "drinking behavior", "marijuana legalization", "marijuana use", "novel virus", "parent grant", "parent project", "psychosocial", "public health emergency", "resilience", "social", "stressor", "substance misuse" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }